The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial
Abstract
Background Afatinib, an irreversible ErbB-family blocker, has shown preclinical activity when tested in EGFR mutant models with mutations that confer resistance to EGFR tyrosine-kinase inhibitors. We aimed to assess its efficacy in patients with advanced lung adenocarcinoma with previous treatment failure on EGFR tyrosine-kinase inhibitors.Methods In this phase 2b/3 trial, we enrolled patients with stage IIIB or IV adenocarcinoma and an Eastern Cooperative Oncology Group performance (ECOG) performance score of 0-2 who had received one or two previous chemotherapy regimens and had disease progression after at least 12 weeks of treatment with erlotinib or gefitinib. We used a computer-generated sequence to randomly allocate patients (2:1) to either afatinib (50 mg per day) or placebo; all patients received best supportive care. Randomisation was done in blocks of three and was stratified by sex and baseline ECOG performance status (0-1 vs 2). Investigators, patients, and the trial sponsor were masked to treatment assignment. The primary endpoint was overall survival (from date of randomisation to death), analysed on an intention-to-treat basis. This study is registered with ClinicalTrials.gov, number NCT00656136.Findings Between May 26, 2008, and Sept 21, 2009, we identified 697 patients, 585 of whom were randomly allocated to treatment (390 to afatinib, 195 to placebo). Median overall survival was 10·8 months (95% CI 10·0-12·0) in the afatinib group and 12·0 months (10·2-14·3) in the placebo group (hazard ratio 1·08, 95% CI 0·86-1·35; p=0·74). Median progression-free survival was longer in the afatinib group (3·3 months, 95% CI 2·79-4·40) than it was in the placebo group (1·1 months, 0·95-1·68; hazard ratio 0·38, 95% CI 0·31-0·48; p<0·0001). No complete responses to treatment were noted; 29 (7%) patients had a partial response in the afatinib group, as did one patient in the placebo group. Subsequent cancer treatment was given to 257 (68%) patients in the afatinib group and 153 (79%) patients in the placebo group. The most common adverse events in the afatinib group were diarrhoea (339 [87%] of 390 patients; 66 [17%] were grade 3) and rash or acne (305 [78%] patients; 56 [14%] were grade 3). These events occurred less often in the placebo group (18 [9%] of 195 patients had diarrhoea; 31 [16%] had rash or acne), all being grade 1 or 2. Drug-related serious adverse events occurred in 39 (10%) patients in the afatinib group and one (<1%) patient in the placebo group. We recorded two possibly treatment-related deaths in the afatinib group.Interpretation Although we recorded no benefit in terms of overall survival with afatinib (which might have been affected by cancer treatments given after progression in both groups), our findings for progression-free survival and response to treatment suggest that afatinib could be of some benefit to patients with advanced lung adenocarcinoma who have failed at least 12 weeks of previous EGFR tyrosine-kinase inhibitor treatment.Funding Boehringer Ingelheim Inc.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, as monotherapy, they have failed to overcome T790M-mediated resistance in patients (28, 29), because concentrations at which these irreversible TKIs overcome T790M activity pre-clinically are not achievable in humans due to dose-limiting toxicity related to non-selective inhibition of wild-type EGFR (30).”
From AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer (2014) · cites this paper as [28]
In the citing paper
“However, we know from clinical experience that afatinib is unable to inhibit T790M in the clinic due to a lack of a therapeutic window”
In the citing paper
“For example, studies of afatinib monotherapy showed a response rate of less than 10% among patients with acquired resistance to erlotinib or gefitinib, with a progression-free survival of approximately 4 months.13,15”
From Rociletinib in EGFR-Mutated Non–Small-Cell Lung Cancer (2015) · cites this paper as [13]
In the citing paper
“However, in lung cancer patients, afatinib is only effective in EGFR TKI naive EGFR mutant cancers and has a RR of < 10% in patients with NSCLC that have developed resistance to gefitinib or erlotinib (13).”
From EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors (2015) · cites this paper as [13]
In the citing paper
“neither Afatinib [76] nor Neratinib [77] nor Dacomitinib [78] demonstrated significant activity as single agent in patients harboring the T790M mutations.”
From A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives (2015) · cites this paper as [76]
In the citing paper
“However, for EGFR T790M mutated lung cancer, it failed to overcome EGFR T790M-mediated resistance in patients [36, 37].”
In the citing paper
“Sixty-three percent of the patients in the afatinib group and 76% in the control group received ≥ one subsequent regimen (all mutation statuses).15”
From Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update (2015) · cites this paper as [15]
In the citing paper
“Response rate was 7% versus 0.5%.”
From Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update (2015) · cites this paper as [15]
In the citing paper
“In a prespecified analysis, participants with a complete or partial response to a first-line EGFR TKI whose tumors also had known EGFR mutation test results (58 [88%] of 66), the HR for PFS was significant (0.23), but the HR for OS was not (0.90) in the afatinib arm.”
From Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update (2015) · cites this paper as [15]
In the citing paper
“Some of the second-line studies included patients who had received > two previous regimens.15,23,47,48,51,65”
From Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update (2015) · cites this paper as [15]
In the citing paper
“The study found no improvement in the primary end point of OS between patients randomly assigned to afatinib and those randomly assigned to placebo, although PFS was longer in the afatinib group (3.3 v 1.1 months; HR, 0.38; 95% CI, 0.31 to 0.48; P < .001).”
From Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update (2015) · cites this paper as [15]
In the citing paper
“Among these 96 patients, PFS was 3.3 months for those who received afatinib and 1.0 month for those who received placebo (HR, 0.55; 95% CI, 0.31 to 0.85; P = .009).15”
From Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update (2015) · cites this paper as [15]
Citations
Cites
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Self-citationErlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419
Self-citationScagliotti, G. V., Parikh, P., von Pawel, J., Biesma, B., Vansteenkiste, J., Manegold, C., Serwatowski, P., Gatzemeier, U., Digumarti, R., Zukin, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.0375 · Cited by 3,203
Self-citationFayers, P. M., Aaronson, N. K., Bjordal, K., Groenvold, M., Curran, D., & Bottomley, A. (2001) · Research at the University of Copenhagen (University of Copenhagen) · Cited by 2,520
BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
Li, D., Ambrogio, L., Shimamura, T., Kubo, S., Takahashi, M., Chirieac, L. R., Padera, R. F., Shapiro, G. I., Baum, A., Himmelsbach, F., et al. (2008) · Oncogene · doi:10.1038/onc.2008.109 · Cited by 1,447
Pirker, R., Pereira, J. R., Szczęsna, A., von Pawel, J., Krzakowski, M. J., Ramlau, R., Vynnychenko, I. O., Park, K., Yu, C.-T., Ganul, V., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60569-9 · Cited by 1,346
Self-citationRational, biologically based treatment of EGFR-mutant non-small-cell lung cancer
Pao, W., & Chmielecki, J. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2947 · Cited by 1,083
Bergman, B., Aaronson, N. K., Ahmedzai, S. H., Kaasa, S., & Sullivan, M. (1994) · European Journal of Cancer · doi:10.1016/0959-8049(94)90535-5 · Cited by 906
Robins, J. M., & Finkelstein, D. M. (2000) · Biometrics · doi:10.1111/j.0006-341x.2000.00779.x · Cited by 877
Research works printed but not linked: 2
- Hirsh, 2011, Symptom and health-related quality of life benefit from afatinib (BIBW 2992) in advanced NSCLC patients previously treated with erlotinib or gefitinib: results of a randomized phase III study (LUX-Lung 1), Proc World Conf Lung Cancer
- Atagi, 2011, LUX-Lung 4: A phase II trial of afatinib (BIBW 2992) in advanced NSCLC patients previously treated with erlotinib or gefitinib, Proc World Conf Lung Cancer
Cited by
Sorted by citations
Items 501–600 of 988
Protein kinase inhibitors to treat non-small-cell lung cancer
Minuti, G., D’Incecco, A., Landi, L. M., & Cappuzzo, F. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.909412 · Cited by 17
Third- and Further-Line Therapy in Advanced Non-Small-Cell Lung Cancer Patients: an Overview
Genestreti, G., Grossi, F., Genova, C., Burgio, M. A., Bongiovanni, A., Gavelli, G., Bartolotti, M., Battista, M. D., Cavallo, G., & Brandes, A. A. (2014) · Future Oncology · doi:10.2217/fon.14.96 · Cited by 17
Zhang, L., Xue, C., Tian, Y., Zhang, J., Zhao, Y., Zhan, J., & Fang, W. (2016) · Drug Design Development and Therapy · doi:10.2147/dddt.s94432 · Cited by 17
Izumi, M., Costa, D. B., & Kobayashi, S. S. (2024) · Lung Cancer · doi:10.1016/j.lungcan.2024.107885 · Cited by 20
Marshall, J. L., Shapiro, G. I., Uttenreuther‐Fischer, M., Ould-Kaci, M., Stopfer, P., & Gordon, M. S. (2013) · Future Oncology · doi:10.2217/fon.12.195 · Cited by 17
Ke, E., & Wu, Y.-L. L. C. (2016) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753465816634545 · Cited by 17
Vyse, S., Howitt, A., & Huang, P. H. (2017) · Journal of Molecular Biology · doi:10.1016/j.jmb.2017.04.018 · Cited by 16
Satouchi, M., Tanaka, H., Yoshioka, H., Shimokawaji, T., Mizuno, K., Takeda, K., Yoshino, I., Seto, T., Kurata, T., Tashiro, N., et al. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.07.015 · Cited by 17
Yoon, B. W., Kim, J., Lee, S. H., Choi, C., Rho, J. K., Yoon, S., Lee, K. H., Kim, S., Jang, T. W., & Lee, J. C. (2019) · Translational Oncology · doi:10.1016/j.tranon.2019.04.004 · Cited by 17
Self-citationYuan, Y., Li, X., Chen, J., Dong, Weng, S., & Huang, J. (2014) · OncoTargets and Therapy · doi:10.2147/ott.s34124 · Cited by 17
Jia, Y., Ali, S. M., Saad, S., Chan, C. A., Miller, V. A., & Halmos, B. (2014) · Cancer Biology & Therapy · doi:10.4161/cbt.29173 · Cited by 17
Self-citationBorriello, A., Caldarelli, I., Bencivenga, D., Stampone, E., Perrotta, S., Oliva, A., & Ragione, F. D. (2016) · Oncotarget · doi:10.18632/oncotarget.12649 · Cited by 16
Role of afatinib in the treatment of advanced lung squamous cell carcinoma
Vavalà, T. (2017) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s112715 · Cited by 19
Xu, Y., Zhang, F., Pan, X., Wang, G., Zhu, L., Zhang, J., Wen, D., & Lu, S. (2018) · 癌症：英文版 · doi:10.1186/s40880-018-0284-1 · Cited by 16
Carrera, P. M., & Ormond, M. (2015) · Maturitas · doi:10.1016/j.maturitas.2015.04.008 · Cited by 17
Vansteenkiste, J., & Wauters, E. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx724 · Cited by 17
Emerging Options for the Management of Non-Small Cell Lung Cancer
Binder, D., & Hegenbarth, K. (2013) · Clinical Medicine Insights Oncology · doi:10.4137/cmo.s10269 · Cited by 17
Pharmacotherapy targeting the EGFR oncogene in NSCLC
Landi, L. M., & Cappuzzo, F. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.957179 · Cited by 17
Rodrigues, H. V., Ke, D., Lim, J. T., Stephen, B., Bellido, J., Jankú, F., Zinner, R., Tsimberidou, A. M., Hong, D. S., Piha-Paul, S. A., et al. (2015) · Investigational New Drugs · doi:10.1007/s10637-015-0238-2 · Cited by 16
Abdel-Rahman, O. M., & Fouad, M. (2015) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2015.1014035 · Cited by 17
Califano, R., Romanidou, O., Mountzios, G., Landi, L. M., Cappuzzo, F., & Blackhall, F. H. (2016) · Drugs · doi:10.1007/s40265-016-0578-z · Cited by 16
Sun, J., & Park, K. (2017) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000350 · Cited by 16
Self-citationNovel Egfr (T790M)-Cmet Dual Inhibitors: Putative Therapeutic Agents for Non-Small-Cell Lung Cancer
Singh, P. K., & Silakari, O. (2017) · Future Medicinal Chemistry · doi:10.4155/fmc-2016-0234 · Cited by 16
Nanamiya, R., Saito, R., Miki, Y., Inoue, C., Asavasupreechar, T., Abe, J., Sato, I., & Sasano, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168522 · Cited by 16
Fregni, M., Ciribilli, Y., & Zawacka‐Pankau, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23137213 · Cited by 16
An, B., Fan, Y., Wei, L., Nie, W., Nie, W., Wang, M., Feng, J., Yao, H., Zhang, Y., Li, X., et al. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.106653 · Cited by 16
Self-citationKu, B. M., Bae, Y.-H., Koh, J., Sun, J., Lee, S.-H., Ahn, J. S., Park, K., & Ahn, M. (2016) · Investigational New Drugs · doi:10.1007/s10637-016-0350-y · Cited by 16
Self-citationStrategies to Overcome Acquired Resistances Conferred by Mutations in the Kinase Domain of Egfr
Lim, S. M., Jeong, Y., & Hong, S. (2016) · Future Medicinal Chemistry · doi:10.4155/fmc-2016-0019 · Cited by 16
The safety of afatinib for the treatment of non-small cell lung cancer
Barrón, F., de la Torre-Vallejo, M., Luna-Palencia, R. L., Cardona, A. F., & Arrieta, O. G. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2016.1236910 · Cited by 16
Aggarwal, C., & Borghaei, H. (2017) · The Oncologist · doi:10.1634/theoncologist.2016-0345 · Cited by 16
Jain, P., Khanal, R., Sharma, A., Yan, F., & Sharma, N. (2014) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2014.983083 · Cited by 17
Chang, Y., Kim, S. Y., Choi, Y. J., So, K. S., Rho, J. K., Kim, W. S., Lee, J. C., Chung, J.-H., & Choi, C. (2013) · Tuberculosis & respiratory diseases · doi:10.4046/trd.2013.75.3.95 · Cited by 16
Self-citationMartin, P., Stewart, E., Pham, N., Mascaux, C., Panchal, D., Li, M., Kim, L., Sakashita, S., Wang, D. Y. Q., Sykes, J. R., et al. (2016) · Clinical Lung Cancer · doi:10.1016/j.cllc.2016.01.002 · Cited by 16
Uchibori, K., Satouchi, M., Sueoka‐Aragane, N., Urata, Y., Sato, A., Imamura, F., Inoue, T., TACHIHARA, M. Y., Kobayashi, K., Katakami, N., et al. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.07.031 · Cited by 16
Horn, L., Eisenberg, R., Gius, D. R., Kimmelshue, K. N., Massion, P. P., Putnam, J. B., Robinson, C. G., & Carbone, D. P. (2014) · Elsevier eBooks · doi:10.1016/b978-1-4557-2865-7.00072-2 · Cited by 16
Emerging combination therapies to overcome resistance in EGFR-driven tumors
Ratti, M., & Tomasello, G. (2013) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000035 · Cited by 15
Lee, K., Lai, T., Lee, W.-J., Chen, Y.-C., Ho, K., Hung, W.-Y., Yang, Y., Chan, M., Hsieh, F.-K., Chung, C., et al. (2023) · Cancers · doi:10.3390/cancers15133288 · Cited by 16
Self-citationFirst-Line Management of EGFR-Mutated Advanced Lung Adenocarcinoma: Recent Developments
Liao, B.-C., Lin, C., & Yang, J. C. (2013) · Drugs · doi:10.1007/s40265-013-0020-8 · Cited by 16
Self-citationSpicer, J. F., Baird, R. D., Suder, A., Cresti, N., Corbacho, J. G., Hogarth, L., Frenkel, E. P., Matsumoto, S., Kawabata, I., Donaldson, K., et al. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2014.11.003 · Cited by 15
Arrieta, O. G., Cruz‐Rico, G., Soto‐Pérez‐de‐Celis, E., Ramírez-Tirado, L.-A., Caballé‐Perez, E., Martínez-Hernández, J.-N., Martinez-Alvarez, I., Soca‐Chafre, G., Macedo-Pérez, E. O., & la Vega, H. A. (2016) · Targeted Oncology · doi:10.1007/s11523-016-0425-x · Cited by 15
Cappuzzo, F., Soo, R. A., Hochmair, M. J., Schüler, M., Lam, K. C., Stehle, G., Cseh, A., Lorence, R. M., Linden, S., Forman, N. D., et al. (2018) · Future Oncology · doi:10.2217/fon-2017-0666 · Cited by 15
Self-citationXie, X., Wang, X., Wu, S., Yang, H., Liu, J., Chen, H., Ding, Y., Ling, L., & Lin, H. (2020) · Journal of Thoracic Disease · doi:10.21037/jtd-19-4000a · Cited by 16
Role of gefitinib in the targeted treatment of non-small-cell lung cancer in Chinese patients
Guan, Y., Li, M., He, Q. W., Li, M., & Luo, F. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s80635 · Cited by 15
Paludan‐Müller, A. S., Créquit, P., & Boutron, I. (2021) · BMC Medicine · doi:10.1186/s12916-021-01955-0 · Cited by 18
Afatinib in Non-Small Cell Lung Cancer.
Wirth, S. M. (2015) · Europe PMC (PubMed Central) · Cited by 15
Zhang, J., Zhang, Y., Tang, S., Liang, H., Chen, D., Jiang, L., He, Q., Huang, Y., Wang, X., Deng, K., et al. (2017) · Annals of Translational Medicine · doi:10.21037/atm.2017.11.24 · Cited by 15
Hu, J., Han, Y., Wang, J., Liu, Y., Zhao, Y., Liu, Y., & Gong, P. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2018.02.029 · Cited by 16
The pre-clinical discovery and development of osimertinib used to treat non-small cell lung cancer
Wittlinger, F., & Laufer, S. (2021) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2021.1936496 · Cited by 15
Guo, Y., Du, Z., & Shi, T. (2023) · Biophysica · doi:10.3390/biophysica3010013 · Cited by 14
Re-Treatment with EGFR-TKIs in NSCLC Patients Who Developed Acquired Resistance
Wu, W.-S., & Chen, Y. (2014) · Journal of Personalized Medicine · doi:10.3390/jpm4030297 · Cited by 14
Self-citationNCCN Guidelines Version 1.2015 Panel Members Non-Small Cell Lung Cancer
Ettinger, D. S., Kimmel, S., Wood, D. E., Akerley, W., Bazhenova, L. A., Borghaei, H., Camidge, D. R., Cheney, R. T., Chirieac, L. R., Jahan, T. M., et al. (2014) · Cited by 14
New strategies to develop new medications for lung cancer and metastasis
Zhao, Y., & Adjei, A. A. (2015) · Cancer and Metastasis Reviews · doi:10.1007/s10555-015-9553-5 · Cited by 14
Seixas, J. D., Sousa, B. B., Marques, M. C., Guerreiro, A., Traquete, R., Rodrigues, T., Albuquerque, I. S., Sousa, M. F. Q., Lemos, A. R., Sousa, P. M. F., et al. (2020) · RSC Chemical Biology · doi:10.1039/d0cb00033g · Cited by 14
Molecular profiling of afatinib-resistant non-small cell lung cancer cells in vivo derived from mice
Chung, C.-T., Yeh, K., Lee, C., Chen, Y., Ho, P.-J., Chang, K.-Y., Chen, C., Lai, Y., & Chen, C. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105183 · Cited by 14
Self-citationHao, Y., Lyu, J., Qu, R., Sun, D., Zhao, Z., Chen, Z., Ding, J., Xie, H., Xu, Y. F., & Li, H. (2017) · Scientific Reports · doi:10.1038/s41598-017-04184-9 · Cited by 14
Li, J., & Gu, J. H. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.12.001 · Cited by 14
Schulz, C. K. J., Gandara, D. R., Berardo, C. G., Rosenthal, R., Foo, J., Morel, C., Ballinger, M. D., Watkins, C. L., & Chu, P. (2019) · Clinical Lung Cancer · doi:10.1016/j.cllc.2019.06.017 · Cited by 14
Strategies for Overcoming EGFR Resistance in the Treatment of Advanced-Stage NSCLC
Lovly, C. M., & Horn, L. (2012) · Current Treatment Options in Oncology · doi:10.1007/s11864-012-0204-6 · Cited by 14
Chemotherapy for advanced cancers.
Rajagopal, P. S., Nipp, R. D., & Selvaggi, K. J. (2014) · PubMed · doi:10.3978/j.issn.2224-5820.2014.06.02 · Cited by 14
Todsaporn, D., Zubenko, A. A., Kartsev, V. G., Mahalapbutr, P., Geronikaki, A. A., Sirakanyan, S. N., Диваева, Л. Н., Chekrisheva, V., Yıldız, İ., Choowongkomon, K., et al. (2024) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.4c06246 · Cited by 15
Zhang, B., Wang, H., Yang, L.-T., Zhang, Y., Wang, P., Huang, G., Zheng, J., Ren, H., & Qin, S. (2016) · Pathology - Research and Practice · doi:10.1016/j.prp.2016.07.011 · Cited by 13
Pharmacological management of relapsed/refractory NSCLC with chemical drugs
Karachaliou, N., Sosa, A. E., Barrón, F., Cao, M. G., Santarpía, M., & Rosell, R. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1285284 · Cited by 13
Abdallah, S. M.-B., & Hirsh, V. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00097 · Cited by 13
Self-citationHe, J., Li, W., Yu, L., & Liu, G. (2020) · Translational Cancer Research · doi:10.21037/tcr-20-1571 · Cited by 13
Arrieta, O. G., Zatarain-Barrón, Z. L., Cardona, A. F., Corrales, L., Martin, C. M., & Cuello, M. (2022) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_349951 · Cited by 13
Chandrasekar, M., Patnaik, S. K., Palathoti, N., Ramamurthi, D., & Swaroop, A. K. (2022) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557522666220512152448 · Cited by 15
Advances in personalized therapy for lung cancer
Kim, E. S., & Pandya, K. J. (2013) · Expert Opinion on Medical Diagnostics · doi:10.1517/17530059.2013.826645 · Cited by 13
Proto, C., Russo, G. L., Corrao, G., Ganzinelli, M., Facchinetti, F., Minari, R., Tiseo, M., & Garassino, M. C. (2017) · Tumori Journal · doi:10.5301/tj.5000663 · Cited by 14
Sun, W., & Li, J. (2019) · Cancer Investigation · doi:10.1080/07357907.2019.1634089 · Cited by 13
Elekofehinti, O. O., Adetoyi, I. R., Popoola, H. O., Ayodeji, F. O., Taiwo, F. A., Akinjiyan, M. O., Koledoye, O. F., Iwaloye, O., & Adegboyega, A. E. (2024) · In Silico Pharmacology · doi:10.1007/s40203-024-00197-1 · Cited by 12
Bian, D. J. H., Lazaratos, A.-M., Maritan, S. M., Quaiattini, A., Zeng, Z., Zhu, Z., Sener, U. T., Malani, R., Kim, Y. J., Ichihara, E., et al. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e29668 · Cited by 12
Harbeck, N., Solca, F., & Gauler, T. C. (2013) · Future Oncology · doi:10.2217/fon.13.244 · Cited by 12
González-Larriba, J. L., Lázaro-Quintela, M., Cobo, M., Dómine, M., Majem, M., & García‐Campelo, R. (2017) · Translational Lung Cancer Research · doi:10.21037/tlcr.2017.10.03 · Cited by 12
Diarrhea With HER2‐Targeted Agents in Cancer Patients: A Systematic Review and Meta‐Analysis
Li, J. (2019) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1382 · Cited by 12
Wu, Z., Chen, S., Du, X., Wu, Y., & Xie, X. (2020) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13281 · Cited by 14
Combined PARP inhibitors and small molecular inhibitors in solid tumor treatment (Review)
Jin, N. Y., Xia, Y., & Gao, Q. (2023) · International Journal of Oncology · doi:10.3892/ijo.2023.5476 · Cited by 12
Generations of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Perils and Progress
Castellanos, E. H., & Horn, L. (2015) · Current Treatment Options in Oncology · doi:10.1007/s11864-015-0365-1 · Cited by 12
Khan, F., Ottensmeier, C. H. H., Popat, S., Dua, D., Dorey, N., Ellis, S. H., Szabo, M., Upadhyay, S., Califano, R., Chan, S., et al. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2014.03.001 · Cited by 12
A new generation of EGFR tyrosine-kinase inhibitors in NSCLC
Hirsch, F. R., & Bunn, P. A. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70124-9 · Cited by 12
A HER 1-2 Punch: Dual EGFR Targeting Deals Resistance a Deadly Blow
Gibbons, D. L., & Byers, L. A. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0791 · Cited by 12
Yang, H., Wang, R., Peng, S., Chen, L., Li, Q., & Wang, W. (2016) · Oncotarget · doi:10.18632/oncotarget.7586 · Cited by 12
Sartori, G., Belluomini, L., Lombardo, F., Avancini, A., Trestini, I., Vita, E., Tregnago, D., Menis, J., Bria, E., Milella, M., et al. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2020.1776119 · Cited by 12
Zhu, Q., Liu, Z., Li, P., & Cheng, Z. (2014) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.dmpk-13-rg-123 · Cited by 12
Selectivity profile of afatinib for EGFR-mutated non-small-cell lung cancer
Wang, D. D., Lee, V. H.-F., Zhu, G., Zou, B., Ma, L., & Yan, H. (2016) · Molecular BioSystems · doi:10.1039/c6mb00038j · Cited by 12
Zhao, X., Pan, S.-Y., Huang, Q., Lu, Y.-N., Wu, X., Chang, J., Liu, Z., Cai, X., Liu, Q., Wang, J., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9891 · Cited by 12
Kita, Y., Go, T., Nakashima, N., Liu, D., Tokunaga, Y., Zhang, X., Nakano, T., Nii, K., Chang, S. S., & Yokomise, H. (2020) · Anticancer Research · doi:10.21873/anticanres.14004 · Cited by 12
Li, W., Yao, H., Gu, C., Ren, Y., Liu, J., An, B., Hu, W., Li, X., & Chan, A. S. C. (2022) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2022.106188 · Cited by 11
Nephrotoxicity of targeted therapy used to treat lung cancer
Li, Q., Lin, J., Hao, G., Xie, A., Liu, S., & Tang, B. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1369118 · Cited by 11
Sun, K., Wang, X., Zhang, H., Lin, G., & Jiang, R. (2024) · Cancer Control · doi:10.1177/10732748241278039 · Cited by 12
Revannasiddaiah, S., Thakur, P., Bhardwaj, B., Susheela, S. P., & Madabhavi, I. (2014) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2072-1439.2014.05.19 · Cited by 11
Suzuki, H., Hirashima, T., Okamoto, N., Yamadori, T., Tamiya, M., Morishita, N., Shiroyama, T., Takeoka, S., Osa, A., Azuma, Y., et al. (2014) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.12199 · Cited by 11
Molecularly targeted therapies for advanced or metastatic non-small-cell lung carcinoma
Bayraktar, S. (2013) · World Journal of Clinical Oncology · doi:10.5306/wjco.v4.i2.29 · Cited by 11
Zaarour, M., Weerasinghe, C. K., Nazha, B., Hassan, S., & Atallah, J. P. (2015) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2015.1092385 · Cited by 11
Chougule, A., & Basak, S. (2017) · Indian Journal of Cancer · doi:10.4103/ijc.ijc_540_17 · Cited by 11
Tanaka, H., Sakamoto, H., Akita, T., Ohyanagi, F., Kawashima, Y., Tambo, Y., Tanimoto, A., Horiike, A., Miyauchi, E., Tsuchiya‐Kawano, Y., et al. (2022) · Thoracic Cancer · doi:10.1111/1759-7714.14415 · Cited by 12
Hashimoto, Y., Maeda, K., Shimomura, O., Miyazaki, Y., Hashimoto, S., Moriyama, A., Oda, T., & Kusuhara, H. (2023) · Toxicology in Vitro · doi:10.1016/j.tiv.2023.105691 · Cited by 11
Araki, T., Kanda, S., Obara, M., Agatsuma, T., Kakizaki, Y., Hama, M., Yamamoto, H., Takada, M., Yamamoto, M., Matsuo, A., et al. (2024) · Respiratory Investigation · doi:10.1016/j.resinv.2024.01.002 · Cited by 11
Favoni, R. E., & Alama, A. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.07.011 · Cited by 11
Ceritinib for Treatment of ALK-Rearranged Advanced Non-Small-Cell Lung Cancer
Vansteenkiste, J. (2014) · Future Oncology · doi:10.2217/fon.14.94 · Cited by 11
Nishiya, N. (2015) · World Journal of Biological Chemistry · doi:10.4331/wjbc.v6.i4.409 · Cited by 11
Metadata
- Authors
- Miller, V. A., Hirsh, V., Cadranel, J., Chen, Y.-M., Park, K., Kim, S.-W., Zhou, C., Su, W.-C., Wang, M., Sun, Y., Heo, D. S., Crino, L., Tan, E.-H., Chao, T.-Y., Shahidi, M., Cong, X. J., Lorence, R. M., & Yang, J. C.-H.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- McGill University Health Centre (CA)
- Assistance Publique – Hôpitaux de Paris (FR)
- Taipei Veterans General Hospital (TW)
- Samsung Medical Center (KR)
- Asan Medical Center (KR)
- Tongji University (CN)
- National Cheng Kung University Hospital (TW)
- Peking Union Medical College Hospital (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Seoul National University Hospital (KR)
- National Cancer Centre Singapore (SG)
- Taipei Medical University-Shuang Ho Hospital (TW)
- Boehringer Ingelheim (United Kingdom) (GB)
- Boehringer Ingelheim (United States) (US)
- National Taiwan University (TW)
- Corresponding author
- Yang, James Chih-Hsin
- ORCID
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2012-05
- Volume
- 13
- Issue
- 5
- Pages
- 528-538
- ISSN
- 1470-2045 (ISSN-L)
- OpenAlex
- W2152905269
- Cited by
- 961
- References
- 29
- Citations by year
- 2026: 14 · 2025: 14 · 2024: 28 · 2023: 38 · 2022: 33 · 2021: 46 · 2020: 50 · 2019: 57 · 2018: 70 · 2017: 103 · 2016: 99 · 2015: 125 · 2014: 139 · 2013: 107 · 2012: 37
- FWCI
- 105.26
- Type
- journal article
- Language
- en
- Update notices
- erratum (2012-05-01)
- Open access
- closed
- Locations
- The Lancet Oncology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Keywords
- afatinib, non-small cell lung cancer, lung adenocarcinoma, EGFR tyrosine kinase inhibitors, erlotinib, gefitinib, EGFR mutation, EGFR inhibitor resistance, second-line therapy, overall survival, progression-free survival, best supportive care, targeted therapy
- MeSH terms
- Erlotinib Hydrochloride, Gefitinib, Afatinib, Adenocarcinoma, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Double-Blind Method, Female, Humans, Lung Neoplasms, Male, Middle Aged, Quinazolines, Protein Kinase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
